Burney Co. Grows Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Burney Co. raised its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 196.4% in the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 186,359 shares of the specialty pharmaceutical company’s stock after purchasing an additional 123,487 shares during the period. Burney Co. owned 0.34% of Supernus Pharmaceuticals worth $5,602,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the stock. Dimensional Fund Advisors LP lifted its stake in shares of Supernus Pharmaceuticals by 1.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 2,430,916 shares of the specialty pharmaceutical company’s stock valued at $73,073,000 after buying an additional 39,650 shares in the last quarter. Swiss National Bank lifted its holdings in shares of Supernus Pharmaceuticals by 1.5% in the second quarter. Swiss National Bank now owns 118,400 shares of the specialty pharmaceutical company’s stock worth $3,559,000 after buying an additional 1,800 shares in the last quarter. International Biotechnology Trust PLC boosted its position in shares of Supernus Pharmaceuticals by 23.6% during the second quarter. International Biotechnology Trust PLC now owns 523,500 shares of the specialty pharmaceutical company’s stock worth $15,736,000 after acquiring an additional 100,000 shares during the last quarter. Los Angeles Capital Management LLC bought a new position in shares of Supernus Pharmaceuticals during the second quarter worth $725,000. Finally, Hussman Strategic Advisors Inc. increased its holdings in Supernus Pharmaceuticals by 0.6% in the 2nd quarter. Hussman Strategic Advisors Inc. now owns 93,600 shares of the specialty pharmaceutical company’s stock valued at $2,814,000 after acquiring an additional 600 shares during the last quarter.

Insider Buying and Selling

In other news, VP Tami Tillotson Martin sold 8,100 shares of the firm’s stock in a transaction dated Wednesday, August 30th. The shares were sold at an average price of $32.00, for a total value of $259,200.00. Following the sale, the vice president now directly owns 85,249 shares in the company, valued at approximately $2,727,968. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 8.76% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several research analysts have commented on SUPN shares. Piper Sandler increased their price objective on shares of Supernus Pharmaceuticals from $42.00 to $43.00 and gave the company an “overweight” rating in a report on Thursday, November 9th. StockNews.com raised shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, November 9th.

Supernus Pharmaceuticals Price Performance

NASDAQ:SUPN opened at $28.04 on Wednesday. The firm has a market capitalization of $1.53 billion, a price-to-earnings ratio of 68.39 and a beta of 1.08. The business has a 50 day simple moving average of $26.68 and a 200-day simple moving average of $30.47. Supernus Pharmaceuticals, Inc. has a 1 year low of $21.99 and a 1 year high of $42.09.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its earnings results on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.13 by ($0.42). Supernus Pharmaceuticals had a net margin of 4.20% and a return on equity of 2.82%. The business had revenue of $153.88 million for the quarter, compared to analysts’ expectations of $143.39 million. During the same quarter last year, the firm earned $0.03 EPS. The firm’s quarterly revenue was down 13.2% on a year-over-year basis. As a group, analysts expect that Supernus Pharmaceuticals, Inc. will post 1.59 earnings per share for the current fiscal year.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age.